Asterand operates a biorepository, but cast out of your mind any visions of pickled livers and brains floating in large clear jars. Asterand, Inc. collects donated specimens of diseased tissue and sells them to researchers to help them better understand and treat such ailments as prostate, breast, and lung cancer, as well as autoimmune, cardiovascular, inflammatory, psychiatric, and respiratory conditions. In addition to supplying these biological samples to researchers, Asterand offers such services as high-throughput screening to speed drug discovery and collaborative research. Asterand, Inc. acquired Pharmagene in a reverse merger.

Virbac Corporation makes animal health and pet-care products and sells them to veterinarians and retailers. For dogs and cats it makes C.E.T dental products, Allederm dermatological products, and digestive and hairball remedies. The company's Iverhart medication prevents heartworms in dogs. Virbac also makes antibiotics, dewormer, and euthanasia products. Its other brands include Biomox, Clintabs, and Vetasyl. In addition to producing its own animal health products, the company provides contract manufacturing through subsidiary PM Resources. The company is owned by Virbac SA.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

Illumina was founded in 1998 and is headquartered in San Diego, California. Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include Genome Analyzer II, an instrument for high-throughput sequencing using Illumina sequencing by synthesis technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company's consumables comprise Standard Sequencing Kit, a reagent used for sequencing by synthesis chemistry on the Genome Analyzer; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200—500 kb insert paired-end reads; InfiniumHD Whole-Genome BeadChips comprising Human1M-Duo, Human610-Quad, Human660W-Quad, and HumanCytoSNP-12, which are multi-sample DNA analysis microarrays that interrogate up to 1.2 million markers per sample; iSelect Custom Genotyping BeadChips that are customer designable SNP genotyping arrays for 6,000 to 200,000 markers; and Whole-Genome Gene Expression BeadChips, which are multi-sample expression profiling arrays with up-to-date content for human, mouse, and rat.

Threshold Pharmaceuticals, Inc. company was founded in 2001 and is headquartered in Redwood City, California. Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Its product line includes TH-302, a product candidate in phase I/II for the potential treatment of patients with cancer; Glufosfamide for the treatment of pancreatic cancer; and 2DG, a phase I product candidate for the treatment of patients with cancer.

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and Ereska™ (intranasal ketamine).

Response Genetics Inc. company was founded in 1999 and is headquartered in Los Angeles, California. Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suite, which comprises KRAS Mutation and EGFR Amplification tests. The KRAS Mutation test identifies tumors that have low probability of response to EGFR-directed therapy. The EGFR Amplification test assesses the probability of benefit from EGFR-directed therapy. The company also offers ResponseDX: Colon test suite that includes ERCC1, KRAS Mutation, and TS tests. The ERCC1 test is a test for the probability of response to platin-based therapies and the analysis of RRM1 tests for the probability of response to gemcitabine-based therapies. The TS test measures the probability of response to 5-fluorouracil -based chemotherapy. In addition, Response Genetics, Inc. is developing tests of other types of cancer that identify genetic profiles of tumors that recur after surgery. The company has collaboration agreements with Shanghai BioChip Company, Ltd. to provide pharmacogenomic testing services in China using the company's RGI-1 extraction technology; and Hitachi Chemical Co., Ltd. to use its techniques to extract genetic information from formalin-fixed paraffin-embedded tissue samples. It offers its services in the areas of oncology for oncologists, hospitals, and physician offices through the sales force.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

RBC Life Sciences, Inc. was founded in 1988 and is headquartered in Irving, Texas. RBC Life Sciences, Inc., together with its subsidiaries, markets and distributes nutritional supplements and personal care products primarily in the United States, the former Soviet Union, and Canada. It operates in two segments, Nutritional Products and Medical Products. The Nutritional Products segment provides a line of approximately 75 nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life Sciences brand. It markets these products in various categories comprising wellness products, weight loss products, fitness products, and skin care products. This segment markets its products through a network of independent associates, as well as through licensing arrangements with third parties. The Medical Products segment markets a line of approximately 28 wound care products under the MPM Medical brand name.RBC Life Sciences's products include cleansers, dressings, hydrogels, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine, as well as other products, which reduce destruction to skin and tissue caused by radiation, and to reduce pain and itching caused by radiation reactions in the skin and the internal mucosa caused by radiation reactions or reactions to certain cancer medications. Its wound care products are used for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions, as well as to manage pain associated with these wounds in the acute care, long-term care, oncology, and podiatry markets. This segment distributes products to hospitals, nursing homes, clinics, pharmacies, and home health care agencies through medical/surgical supply dealers and pharmaceutical distributors.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.